← Leaderboards
Carlo Ballatore
University Of Pennsylvania
$3,618,196
Attributed
$7,596,589
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2013–22$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,596,589 · 5
By mechanism
U01$3,963,784 · 1
R01$2,330,839 · 1
R21$1,301,966 · 3
Top collaborators
- Kurt R. Brunden11 shared
- Conor Caffrey6 shared
- Anjan Debnath4 shared
- Larissa M. Podust2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Kurt R. Brunden$9,865,188
- Amos B Smith$26,356,961
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMicrotubulesStructureNeurodegenerative DisordersLeadMicrotubule Stabilizing AgentIn VitroPropertyProgramsSeriesMouse ModelEvaluationDoseMaximum Tolerated DoseSafetyMicrotubule StabilizationBrainDrug KineticsEfficacy StudyS DiseaseDrug CandidateAnalogNeuronsScreening
Grant awards (17)
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$746,084
U01 · FY2022 · AG
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$311,482
U01 · FY2022 · AG
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasis$197,500
R21 · FY2022 · AI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$851,784
U01 · FY2021 · AG
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasis$237,000
R21 · FY2021 · AI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$159,949
U01 · FY2021 · AG
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$946,116
U01 · FY2020 · AG
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic Diseases$252,094
R21 · FY2020 · AI · contact PI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$948,369
U01 · FY2019 · AG
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseases$193,750
R21 · FY2019 · AI
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic Diseases$189,122
R21 · FY2019 · AI · contact PI
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseases$232,500
R21 · FY2018 · AI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$455,558
R01 · FY2017 · AG
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$464,643
R01 · FY2016 · AG
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$453,496
R01 · FY2015 · AG · contact PI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$478,571
R01 · FY2014 · AG · contact PI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$478,571
R01 · FY2013 · AG · contact PI